Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
2014-004065-25Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in melanoma (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Primary response rate at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-004065-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004065-25.